

TRANSMITTAL OF UTILITY PATENT APPLICATION FOR FILING

■		Certification und	der 37 CFR 1.10 (if applicable)	JC9
E d		942450601US	February 22, 2002	ň
"E	epress Mail	" mailing label number	Date of Deposit	
in a	ın envelope	y that this Transmittal letter, enclosed application with the United States Postal Service "Express Maressed to: Box Patent Application, Commission	n, and any other documents referred to as enclosed here Iail Post Office to Addressee" service under 37 CFR 1.1 her for Patents, Washington, D.C. 20231.	n, are being deposited 0 on the date indicated
<u></u>		enc Rodgers	Cedem Robye	2
(13	ped or prin	ted name of person mailing application)	(Signature of person mailing application)	
CO	MMISSIO	NT APPLICATION ONER FOR PATENTS D.C. 20231	Attorney Docket	No. <u>TSRI 813,1</u>
Sir	:		Customer N	umber <u>002387</u>
Ma	rtin Fried	nerewith for filing is the utility patent applic	eation of inventor(s): Paul Schimmel, Keisuke W	/akasugi and
ijand	Type Of	TRYPTOPHANYL-tRNA SYNTHETAS REGULATION OF ANGIOGENESIS	SE DERIVED POLYPEPTIDES USEFUL FOR	t THE
[] []	Type Of	f Application		
8	This app	dication is:		
d fl and and and fl fl and	<u></u>	an original (nonprovisional) application. a division of prior application Serial No a continuation of prior application Serial N a continuation-in-part of prior application an application claiming priority of U.S. Pr	No Serial No.	
	X The appl	entire disclosure of the prior application is lication and is hereby incorporated by refere	considered as being part of the disclosure of the a	ccompanying
2.	Enclosed	d Application Elements are:		
•	X spec X drav	uplicate copy of this transmittal letter, cification (including claims and abstract) copyings: 1 copy of sh	neet(s) of formal drawings, OR	D
-	a co state	nexecuted declaration or oath for the utility	patent application including a power of attorney, ling power of attorney from a priority application.	OR
	X nucl a.	eotide and/or amino acid sequence X computer readable copy X paper copy Statement verifying above copies		

TRANSMITTAL OF UTILITY PATENT APPLICATION FOR FILING Page 2

3. Enclosed Accompanying Application Pa	Parts are	cation Parts are
---	-----------	------------------

Preliminary Amenda	ment
--------------------	------

- Claim cancellations are indicated in Preliminary Amendment
- X one itemized, stamped, and self-addressed postcard for the PTO Mail Room date stamp.
- ___ English translation document
- __ Information Disclosure Statement including Form PTO-1449 and copies of the citations therein.
- 4. Small entity status
 - ___ Applicant claims small entity status. See 37 CFR 1.27.
- 5 Filing Fees (as calculated below)

	(Col. 1)	(Col. 2)			
For:	Number Filed	Number Filed Number Extra Rate		Fee	
Basic Fee			Spirite Hall and	\$	740
Total Claims	28 — 20	= 8	x \$ 18 =	\$	144
Independent Claims	7 — 3	= 4	x \$ 84 =	\$	336
Multiple Dependent Claim Presented (if applicable)			+ \$280 =	\$	N/A
			Subtotal	\$	1,220
Reduction by 50% for filing by small entity				\$	N/A
* If the difference in Col. 1 is less than zero, enter "0" in Col. 2. TOTAL			\$	1,220	

Please charge my Deposit Account No. 15-0508 in the amount of \$_____

- \underline{X} A check in the amount of \$1,220.00 to cover the filing fee is enclosed.
- X The Commissioner is authorized to charge payment of the following amounts associated with this communication or credit any overpayment to Deposit Account No. 15-0508:
 - X Additional filing fees under 37 CFR 1.16 or deficiencies in remittances therefor.
 - X Additional processing fees under 37 CFR 1.17 or deficiencies in remittances therefor.
- X ONLY if applicant has partially paid the patent issue fee under 37 C.F.R. §1.18, then the <u>deficiency</u> shall be charged to Deposit Account No. 15-0508, and the Commissioner is authorized to so charge the Deposit Account.
- X The Commissioner is hereby generally authorized under 37 CFR 1.136(a)(3) to treat any future reply in this or any related application filed pursuant to 37 CFR 1.53 requiring an extension of time as incorporating a request therefor, and the Commissioner is hereby specifically authorized to charge Deposit Account No. 15-0508 for any fee that may be due in connection with such a request for an extension of time.

_				
Date	February	22	2002	

Attorney's Signature

Name and Registration No. Robert J. Ross (Reg. No. 45,058)

Correspondence Address:

OLSON & HIERL, LTD. 20 North Wacker Drive, 36th Floor Chicago, Illinois 60606 Telephone: (312) 580-1180

"Express Mail" Mailing Label No. EV042450601US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Paul Schimmel et al.

Serial No.:

Not Yet Assigned

Art Unit: Unknown

Filed:

February 22, 2002

For:

TRYPTOPHANYL-tRNA SYNTHETASE DERIVED

POLYPEPTIDES USEFUL FOR THE

REGULATION OF ANGIOGENESIS

Examiner:

Unknown

Atty. Docket No.: TSRI 813.1

STATEMENT UNDER 37 CFR 1.821(f)

Box Patent Application Commissioner for Patents Washington, D. C. 20231

Sir:

I hereby state that, to the best of my information and belief, the sequence listing information recorded in computer readable form is identical to the paper copy of the Sequence Listing, submitted in accordance with 37 CFR 1.821 (c) and (e).

Respectfully submitted,

February 22, 2002

Robert J. Ross (Reg. No. 45,058)

OLSON & HIERL, LTD. 20 North Wacker Drive 36th Floor Chicago, Illinois 60606 (312) 580-1180